Cooperative CAR targeting to selectively eliminate AML and minimize escape
Cancer Cell · 2023-11 · 41 (11) · 1871-1891.e6
DOI: 10.1016/j.ccell.2023.09.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2023-11. Verfasst von Sascha Haubner und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Hauptthemen laut MEDLINE: T-Lymphocytes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 131-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) poses a singular challenge for chimeric antigen receptor (CAR) therapy owing to its phenotypic heterogeneity and similarity to normal hematopoietic stem/progenitor cells (HSPCs). Here we expound a CAR strategy intended to efficiently target AML while minimizing HSPC toxicity. Quantification of target expression in relapsed/refractory patient samples and normal HSPCs reveals a therapeutic window for gated co-targeting of ADGRE2 and CLEC12A: We combine an attenuated ADGRE2-CAR with a CLEC12A-chimeric costimulatory receptor (ADCLEC.syn1) to preferentially engage ADGRE2posCLEC12Apos leukemic stem cells over ADGRE2lowCLEC12Aneg normal HSPCs. ADCLEC.syn1 prevents antigen escape in AML xenograft models, outperforms the ADGRE2-CAR alone and eradicates AML despite proximate myelopoiesis in humanized mice. Off-target HSPC toxicity is similar to that of a CD19-CAR and can be mitigated by reducing CAR T cell-derived interferon-γ. Overall, we demonstrate the ability of target density-adapted cooperative CAR targeting to selectively eliminate AML and potentially obviate the need for hematopoietic rescue.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Takeda Development Center Americas, Inc., Lexington, MA 02421, USA.
- Department of Medicine III, University Hospital, LMU Munich, 81377 Munich, Germany.
- Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Haubner, S., Mansilla-Soto, J., Nataraj, S., Kogel, F., Chang, Q., de Stanchina, E., Lopez, M., Ng, M. R., Fraser, K., Subklewe, M., Park, J. H., Wang, X., Rivière, I., & Sadelain, M. (2023). Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell, 41(11), 1871-1891.e6. https://doi.org/10.1016/j.ccell.2023.09.010
Vancouver
Haubner S, Mansilla-Soto J, Nataraj S, Kogel F, Chang Q, de Stanchina E, et al. Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell. 2023;41(11):1871-1891.e6. doi:10.1016/j.ccell.2023.09.010
BibTeX
@article{Haubner2023,
author = {Haubner, Sascha and Mansilla-Soto, Jorge and Nataraj, Sarah and Kogel, Friederike and Chang, Qing and de Stanchina, Elisa and Lopez, Michael and Ng, Mei Rosa and Fraser, Kathryn and Subklewe, Marion and Park, Jae H and Wang, Xiuyan and Rivière, Isabelle and Sadelain, Michel},
title = {Cooperative CAR targeting to selectively eliminate AML and minimize escape},
journal = {Cancer Cell},
year = {2023},
volume = {41},
number = {11},
pages = {1871--1891.e6},
doi = {10.1016/j.ccell.2023.09.010}
}
EUVIMED